Core Viewpoint - The announcement highlights that East China Pharmaceutical's subsidiary, Zhejiang Daor Biotechnology, has developed a groundbreaking drug, DR10624, which has been included in the list of breakthrough therapies for severe hypertriglyceridemia (sHTG) by the National Medical Products Administration (NMPA) of China [1][4]. Drug Information - Drug Name: DR10624 Injection - Registration Category: Class 1 Biopharmaceutical - Acceptance Number: CXSB2300148 - Indication: Severe hypertriglyceridemia (sHTG) [1]. R&D and Registration Status - DR10624 is a globally innovative long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, with clinical research approvals from both China CDE and the US FDA for sHTG [2]. - The Phase II clinical study (DR10624-201) results showed significant triglyceride (TG) reductions: 74.5% in the 12.5mg group, 66.2% in the 25mg group, and 68.9% in the 50mg titration group [2]. - 78.5% of participants experienced TG reductions exceeding 50%, and 89.5% had TG levels below 500 mg/dL [2]. - DR10624 also demonstrated significant improvements in lipid profiles and liver fat content, with a median percentage reduction of up to 67% in liver fat [2][3]. Clinical Advantages - DR10624's innovative tri-target mechanism provides strong lipid-lowering effects and good safety profiles, making it a promising treatment option for sHTG patients [3]. - The drug's efficacy in reducing liver fat and regulating metabolic syndrome is highlighted as a significant clinical advantage [3]. Market Context - sHTG, defined as TG levels exceeding 500 mg/dL, poses significant health risks, including cardiovascular diseases and pancreatitis, with a rising prevalence globally [4]. - Traditional lipid-lowering medications have limited efficacy in reducing TG levels below 500 mg/dL, indicating a clinical need for more effective treatments like DR10624 [4]. Future Steps - Following its inclusion in the breakthrough therapy list, DR10624 must complete further clinical trials and receive approval from the NMPA before market launch [5]. - The company is committed to advancing the drug's development in accordance with national regulations and will keep investors informed of progress [5].

Key Points - Major asset restructuring plans are underway for several companies, including JiaoYun Co. and Dongzhu Ecology, with significant risks of termination noted for Dongzhu Ecology's restructuring efforts [11][12] - ST KeliDa is set to resume trading on January 12, 2026, following a proposed change in its actual controller [5] - NineLink Technology has terminated its major asset restructuring plans due to disagreements on core transaction terms [6] - Companies like Huazhou Laojiao and others have announced substantial profit distributions and performance forecasts, indicating positive growth trends [8][9][10] Focus Area 1: Asset Restructuring - JiaoYun Co. is planning a major asset swap involving its automotive sales and service segments with assets from its controlling shareholder [11] - Dongzhu Ecology is attempting to acquire control of Kai Rui Xing Tong Information Technology but faces significant termination risks due to valuation disagreements [12] - NineLink Technology has decided to halt its plans to acquire a 51% stake in Chengdu Neng Tong Technology after failing to reach consensus on key transaction details [6] Focus Area 2: Trading Resumption and Risk Warnings - ST KeliDa will resume trading on January 12, 2026, after a proposed change in its actual controller [5] - China First Heavy Industries and Oriental Pearl have issued risk warning announcements regarding their stock trading, highlighting the volatility and lack of revenue from certain projects [3][4] Focus Area 3: Performance Forecasts - Huazhou Laojiao expects a net profit of between 235 million to 271 million yuan for 2025, a significant recovery from a loss in the previous year [8] - China Shipbuilding Defense anticipates a net profit increase of 149.61% to 196.88% for 2025, driven by improved production efficiency and revenue from joint ventures [9] - Daotong Technology projects a net profit of 900 million to 930 million yuan for 2025, reflecting a growth of 40.42% to 45.10% [10]

Group 1: Stock Trading and Corporate Actions - Jia Mei Packaging's stock will resume trading on January 12, 2026, after a price increase of 230.48% from December 17, 2025, to January 6, 2026, which led to a temporary suspension for investigation [1] - Yanjiang Co. continues to suspend its stock trading due to uncertainties related to a potential major asset restructuring, with a trading plan expected to be disclosed by January 19, 2026 [1] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [4] - Xianle Health plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [4] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [4] Group 2: Mergers and Acquisitions - Defu Technology has terminated its acquisition of 100% of Luxembourg Copper Foil due to additional restrictions imposed by the Luxembourg Ministry of Economy [2] - Defu Technology intends to acquire at least 51% of Huiru Technology through cash purchase and capital increase, with Huiru becoming a subsidiary post-transaction [3] Group 3: Financial Performance and Forecasts - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, with automotive parts business growth offset by challenges in the home appliance sector [7] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [8] - Qu Mei Home expects negative profit figures for 2025, with a reported loss of approximately 66.93 million yuan for the first nine months of 2025 [9] - Jinzhongzi Liquor forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [10] - Sichuang Electronics predicts a net loss of 265 million to 340 million yuan for 2025, attributed to competitive pressures and delayed customer orders [11] - Wansheng Co. anticipates a net loss for 2025 [12] - Weiyuan Co. expects a net loss for 2025 [13] - Kosen Technology forecasts a net loss for 2025 due to market demand fluctuations and strategic adjustments [13] - Zhongheng Group predicts a net loss for 2025 [13] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, a year-on-year increase of 9.41% [13] Group 4: Shareholder Actions - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades between February 4 and April 30, 2026 [14] - Meidike's shareholder intends to reduce holdings by up to 1% through centralized bidding [14]

Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, aiming for rapid capacity expansion to meet growing downstream demand [2] - Huiru Technology specializes in the R&D, production, and sales of high-performance electrolytic copper foil, with a current production capacity of 20,000 tons per year [2] - East China Pharmaceutical's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3][18] - DR10624 is a globally first-of-its-kind long-acting tri-specific agonist, showing excellent efficacy in reducing triglycerides and eliminating liver fat in clinical trials [3][18] Group 2 - Xiantan Co. reported a 9.41% year-on-year increase in chicken product sales revenue, reaching 529 million yuan, with sales volume up by 6.76% [4][19] - Jiamei Packaging's stock will resume trading on January 12 after completing a review during its suspension, with a significant price increase of 230.48% during the suspension period [5][20] - Xianle Health plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange, considering the interests of existing shareholders [6][21][22] Group 3 - China Shipbuilding Defense expects a net profit increase of 149.61% to 196.88% for 2025, projecting a profit of 940 million to 1.12 billion yuan [7][23] - Daotong Technology anticipates a net profit growth of 40.42% to 45.10% for 2025, with a projected profit of 900 million to 930 million yuan [8][24] - Huace Navigation forecasts a net profit increase of 14.84% to 18.27% for 2025, estimating a profit of 670 million to 690 million yuan [9][25] Group 4 - Luokai Co. won a procurement project from State Grid Fujian Electric Power, with a total contract value of approximately 48.2 million yuan [10][26] - Minhe Co. reported a 65.22% year-on-year increase in the sales volume of commodity broiler chicks, totaling approximately 29.66 million chicks, with sales revenue up by 53.09% [11][27] - Zhenghai Bio obtained a medical device registration certificate for calcium silicate bio-ceramic oral bone repair materials, suitable for alveolar bone defect repair [12][28] - Three Gorges Energy reported a cumulative total power generation increase of 5.99% for 2025, with a total generation of 762.61 billion kWh [13][29] - Huisheng Bio expects a net profit of 235 million to 271 million yuan for 2025, marking a turnaround from a loss in the previous year [14][30]

Major Events - Defu Technology announced the termination of the acquisition of 100% equity in Luxembourg Copper Foil due to additional restrictions imposed by the Luxembourg Ministry of Economy, with a contract deposit of €17.4047 million to be fully refunded within 10 working days after termination [1] - China Nonferrous Mining expects a total copper production of approximately 484,000 tons in 2026, including 134,000 tons of cathode copper and 350,000 tons of crude/anode copper, with a decrease in crude/anode copper production due to planned maintenance [3] - Huadong Medicine's subsidiary, Zhejiang Daor Biotechnology, has its DR10624 injection included in the breakthrough therapy designation list for severe hypertriglyceridemia, with clinical research approvals from China CDE and the US FDA [4] Performance - Xiantan Co. reported chicken product sales revenue of CNY 530 million in December 2025, with a year-on-year increase of 9.41% and a sales volume of 55,100 tons [5] - Jinzizi Liquor expects to report a net loss for the fiscal year 2025, although the loss is anticipated to narrow compared to the previous year [6] - Dechang Co. forecasts a net profit of CNY 160 million to CNY 200 million for 2025, representing a year-on-year decrease of 51% to 61% [7] Stock Suspension and Resumption - Jiamei Packaging's stock will resume trading on January 12, 2026, after a price increase of 230.48% from December 17, 2025, to January 6, 2026, leading to a temporary suspension for investigation [8] - Yanjing Co. continues to suspend trading due to uncertainties related to asset acquisition plans, with an expected disclosure of the transaction plan by January 19, 2026 [9]

Core Viewpoint - The announcement highlights the inclusion of DR10624, a novel long-acting tri-target agonist developed by Zhejiang Daor Bio, in the list of breakthrough therapies for severe hypertriglyceridemia (sHTG), indicating significant potential for addressing this public health issue [1]. Group 1: Product Development and Clinical Research - DR10624 is a first-in-class tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, with clinical research approvals from China's CDE and the US FDA for sHTG [1]. - The Phase II clinical study (DR10624-201) results are set to be presented at the 2025 American Heart Association Scientific Sessions, showcasing its innovative approach in treating sHTG [1]. Group 2: Clinical Efficacy and Safety - Clinical data from the DR10624-201 study demonstrate strong lipid-lowering effects and good safety profiles, with additional benefits in reducing liver fat and metabolic regulation [2]. - Traditional lipid-lowering medications have limited efficacy in reducing triglyceride levels below 500 mg/dL, highlighting the need for more effective treatments like DR10624 [2]. Group 3: Public Health Implications - The increasing prevalence of hypertriglyceridemia, with approximately 10% of adults affected globally, underscores the urgent need for better therapeutic options for sHTG, which is associated with serious health risks [2][3]. - DR10624's potential to significantly lower triglycerides and improve inflammatory lipid profiles positions it as a promising innovative therapy for sHTG and related metabolic diseases [3].

Group 1 - Jia Mei Packaging's stock will resume trading on January 12, 2026, after completing a review due to a 230.48% price increase from December 17, 2025, to January 6, 2026 [1] - Yan Jiang Co. continues to suspend trading as it plans to acquire assets, with a disclosure expected by January 19, 2026 [2] - Defu Technology terminated its acquisition of 100% of Luxembourg Copper Foil due to restrictions from the Luxembourg Ministry of Economy, with a refund of €17.4047 million expected [3] Group 2 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash and capital increase, with Huiru focusing on high-performance electrolytic copper foil [4] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [5] - Xianle Health intends to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [6] Group 3 - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital, with a potential cancellation of unsold shares [7] - Fangsheng Pharmaceutical's production facility failed a GMP compliance check, but it will not significantly impact operations [8][9] - East China Pharmaceutical's subsidiary's product has been included in the list of breakthrough therapeutic varieties for severe hypertriglyceridemia [10] Group 4 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, primarily due to competitive pressures and foreign exchange losses [12] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [13] - Qu Mei Home expects a net loss for 2025, with significant negative figures reported for the first nine months [14] Group 5 - Jinzongzi Wine forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [15] - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for 2025, attributed to market competition and delayed orders [16] - Wansheng Co. anticipates a net loss for 2025 [17] - Weiyuan Co. also expects a net loss for 2025 [19] - Kosen Technology predicts a net loss for 2025 due to low capacity utilization and strategic adjustments [20] - Zhongheng Group expects a net loss for 2025 [21] Group 6 - Xiantan Co. reported a 9.41% year-on-year increase in chicken product sales revenue to 530 million yuan in December 2025 [22] Group 7 - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades [24] - Meidike shareholders plan to reduce their holdings by up to 1% through market transactions [25]

Core Viewpoint - East China Pharmaceutical (000963.SZ) announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has developed a first-in-class (FIC) long-acting tri-target agonist, DR10624, which has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) for the treatment of severe hypertriglyceridemia (sHTG) [1] Group 1 - The long-acting tri-target agonist DR10624 targets three receptors: Fibroblast Growth Factor 21 Receptor (FGF21R), Glucagon Receptor (GCGR), and Glucagon-like Peptide-1 Receptor (GLP-1R) [1]

Core Viewpoint - East China Pharmaceutical (华东医药) announced that its subsidiary, Zhejiang Daer Biotechnology Co., Ltd., has developed a first-in-class (FIC) long-acting triple-target agonist, DR10624, targeting Fibroblast Growth Factor 21 Receptor (FGF21R), Glucagon Receptor (GCGR), and Glucagon-like Peptide-1 Receptor (GLP-1R), which has been included in the list of breakthrough therapies for the treatment of severe hypertriglyceridemia (sHTG) [1] Group 1 - The long-acting triple-target agonist DR10624 is a novel therapeutic candidate developed by the company [1] - The drug targets three specific receptors: FGF21R, GCGR, and GLP-1R, indicating a multi-faceted approach to treatment [1] - The inclusion of DR10624 in the breakthrough therapy category highlights its potential significance in addressing severe hypertriglyceridemia [1]

证券代码：000963 证券简称：华东医药 公告编号：2026-001 华东医药股份有限公司 近日，根据国家药品监督管理局药品审评中心（CDE）发布的公 示信息，华东医药股份有限公司（以下简称"公司"）控股子公司浙 江道尔生物科技有限公司（以下简称"道尔生物"）自主研发的同类首 创（FIC）的靶向成纤维细胞生长因子 21 受体（Fibroblast growth factor 21 receptor，FGF21R），胰高血糖素受体（Glucagon receptor，GCGR）， 和胰高血糖素样肽-1 受体（Glucagon-like peptide-1 receptor，GLP-1R) 的长效三靶点激动剂 DR10624 被纳入突破性治疗品种，拟定适应症 为重度高甘油三酯血症（severe hypertriglyceridemia，sHTG），现将 有关详情公告如下： 一、该药物基本信息 药物名称：DR10624 注射液 注册分类：治疗用生物制品 1 类 受理号：CXSB2300148 拟定适应症（或功能主治）：适用于重度高甘油三酯血症 理由及依据：建议同意纳入突破性治疗程序。理由如下：经加快 审议会议议定 ...